nodes	percent_of_prediction	percent_of_DWPC	metapath
Ifosfamide—CYP2C8—Mometasone—systemic scleroderma	0.17	0.355	CbGbCtD
Ifosfamide—CYP2C9—Leflunomide—systemic scleroderma	0.0762	0.159	CbGbCtD
Ifosfamide—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.0702	0.147	CbGbCtD
Ifosfamide—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.0675	0.141	CbGbCtD
Ifosfamide—CYP2C19—Prednisone—systemic scleroderma	0.0453	0.0947	CbGbCtD
Ifosfamide—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0274	0.0573	CbGbCtD
Ifosfamide—CYP3A4—Prednisone—systemic scleroderma	0.0219	0.0458	CbGbCtD
Ifosfamide—CYP2C9—cardial valve—systemic scleroderma	0.0103	0.46	CbGeAlD
Ifosfamide—PTGS1—artery—systemic scleroderma	0.00141	0.063	CbGeAlD
Ifosfamide—CYP2C18—digestive system—systemic scleroderma	0.00135	0.0604	CbGeAlD
Ifosfamide—PTGS1—endothelium—systemic scleroderma	0.00119	0.0532	CbGeAlD
Ifosfamide—PTGS1—blood vessel—systemic scleroderma	0.0011	0.049	CbGeAlD
Ifosfamide—CYP2A6—lung—systemic scleroderma	0.000744	0.0333	CbGeAlD
Ifosfamide—CYP2C19—digestive system—systemic scleroderma	0.000573	0.0257	CbGeAlD
Ifosfamide—PTGS1—connective tissue—systemic scleroderma	0.000562	0.0251	CbGeAlD
Ifosfamide—CYP2B6—skin of body—systemic scleroderma	0.000561	0.0251	CbGeAlD
Ifosfamide—PTGS1—smooth muscle tissue—systemic scleroderma	0.000514	0.023	CbGeAlD
Ifosfamide—PTGS1—skin of body—systemic scleroderma	0.000507	0.0227	CbGeAlD
Ifosfamide—CYP3A5—digestive system—systemic scleroderma	0.000452	0.0202	CbGeAlD
Ifosfamide—CYP2B6—digestive system—systemic scleroderma	0.000449	0.0201	CbGeAlD
Ifosfamide—CYP2C9—digestive system—systemic scleroderma	0.000444	0.0199	CbGeAlD
Ifosfamide—PTGS1—digestive system—systemic scleroderma	0.000406	0.0182	CbGeAlD
Ifosfamide—PTGS1—tendon—systemic scleroderma	0.000386	0.0173	CbGeAlD
Ifosfamide—CYP3A5—lung—systemic scleroderma	0.000377	0.0169	CbGeAlD
Ifosfamide—CYP2B6—lung—systemic scleroderma	0.000375	0.0168	CbGeAlD
Ifosfamide—CYP3A4—digestive system—systemic scleroderma	0.000339	0.0152	CbGeAlD
Ifosfamide—PTGS1—lung—systemic scleroderma	0.000339	0.0152	CbGeAlD
Ifosfamide—Skin disorder—Lisinopril—systemic scleroderma	0.000237	0.000475	CcSEcCtD
Ifosfamide—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000237	0.000474	CcSEcCtD
Ifosfamide—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000236	0.000473	CcSEcCtD
Ifosfamide—Diarrhoea—Captopril—systemic scleroderma	0.000236	0.000473	CcSEcCtD
Ifosfamide—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000236	0.000472	CcSEcCtD
Ifosfamide—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000236	0.000472	CcSEcCtD
Ifosfamide—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000235	0.00047	CcSEcCtD
Ifosfamide—Feeling abnormal—Leflunomide—systemic scleroderma	0.000234	0.000469	CcSEcCtD
Ifosfamide—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000234	0.000469	CcSEcCtD
Ifosfamide—Fatigue—Mycophenolic acid—systemic scleroderma	0.000234	0.000468	CcSEcCtD
Ifosfamide—Nausea—Mometasone—systemic scleroderma	0.000233	0.000467	CcSEcCtD
Ifosfamide—Anorexia—Lisinopril—systemic scleroderma	0.000233	0.000467	CcSEcCtD
Ifosfamide—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000233	0.000466	CcSEcCtD
Ifosfamide—Constipation—Mycophenolic acid—systemic scleroderma	0.000232	0.000465	CcSEcCtD
Ifosfamide—Pain—Mycophenolic acid—systemic scleroderma	0.000232	0.000465	CcSEcCtD
Ifosfamide—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000232	0.000464	CcSEcCtD
Ifosfamide—Hyperglycaemia—Prednisone—systemic scleroderma	0.00023	0.000461	CcSEcCtD
Ifosfamide—Cough—Mycophenolate mofetil—systemic scleroderma	0.000229	0.000458	CcSEcCtD
Ifosfamide—Hypotension—Lisinopril—systemic scleroderma	0.000228	0.000457	CcSEcCtD
Ifosfamide—Dizziness—Captopril—systemic scleroderma	0.000228	0.000457	CcSEcCtD
Ifosfamide—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000227	0.000455	CcSEcCtD
Ifosfamide—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000227	0.000454	CcSEcCtD
Ifosfamide—Urticaria—Leflunomide—systemic scleroderma	0.000226	0.000452	CcSEcCtD
Ifosfamide—Abdominal pain—Leflunomide—systemic scleroderma	0.000225	0.00045	CcSEcCtD
Ifosfamide—Body temperature increased—Leflunomide—systemic scleroderma	0.000225	0.00045	CcSEcCtD
Ifosfamide—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000224	0.000449	CcSEcCtD
Ifosfamide—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000224	0.000448	CcSEcCtD
Ifosfamide—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000223	0.000447	CcSEcCtD
Ifosfamide—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000223	0.000447	CcSEcCtD
Ifosfamide—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000223	0.000447	CcSEcCtD
Ifosfamide—Myocardial infarction—Prednisone—systemic scleroderma	0.000223	0.000447	CcSEcCtD
Ifosfamide—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000223	0.000447	CcSEcCtD
Ifosfamide—Breast disorder—Methotrexate—systemic scleroderma	0.000223	0.000447	CcSEcCtD
Ifosfamide—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000223	0.000446	CcSEcCtD
Ifosfamide—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000222	0.000445	CcSEcCtD
Ifosfamide—Hypersensitivity—Azathioprine—systemic scleroderma	0.000222	0.000444	CcSEcCtD
Ifosfamide—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000222	0.000444	CcSEcCtD
Ifosfamide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000222	0.000444	CcSEcCtD
Ifosfamide—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000221	0.000442	CcSEcCtD
Ifosfamide—Paraesthesia—Lisinopril—systemic scleroderma	0.00022	0.000439	CcSEcCtD
Ifosfamide—Vomiting—Captopril—systemic scleroderma	0.000219	0.000439	CcSEcCtD
Ifosfamide—Dyspnoea—Lisinopril—systemic scleroderma	0.000218	0.000436	CcSEcCtD
Ifosfamide—Rash—Captopril—systemic scleroderma	0.000218	0.000436	CcSEcCtD
Ifosfamide—Dermatitis—Captopril—systemic scleroderma	0.000217	0.000435	CcSEcCtD
Ifosfamide—Somnolence—Lisinopril—systemic scleroderma	0.000217	0.000435	CcSEcCtD
Ifosfamide—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000216	0.000432	CcSEcCtD
Ifosfamide—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000215	0.00043	CcSEcCtD
Ifosfamide—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000215	0.00043	CcSEcCtD
Ifosfamide—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000214	0.000429	CcSEcCtD
Ifosfamide—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000214	0.000429	CcSEcCtD
Ifosfamide—Infection—Mycophenolate mofetil—systemic scleroderma	0.000213	0.000426	CcSEcCtD
Ifosfamide—Decreased appetite—Lisinopril—systemic scleroderma	0.000213	0.000425	CcSEcCtD
Ifosfamide—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000211	0.000423	CcSEcCtD
Ifosfamide—Fatigue—Lisinopril—systemic scleroderma	0.000211	0.000422	CcSEcCtD
Ifosfamide—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00021	0.000421	CcSEcCtD
Ifosfamide—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.00021	0.00042	CcSEcCtD
Ifosfamide—Hypersensitivity—Leflunomide—systemic scleroderma	0.00021	0.00042	CcSEcCtD
Ifosfamide—Pancreatitis—Methotrexate—systemic scleroderma	0.000209	0.000419	CcSEcCtD
Ifosfamide—Pain—Lisinopril—systemic scleroderma	0.000209	0.000419	CcSEcCtD
Ifosfamide—Constipation—Lisinopril—systemic scleroderma	0.000209	0.000419	CcSEcCtD
Ifosfamide—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000208	0.000417	CcSEcCtD
Ifosfamide—Bradycardia—Prednisone—systemic scleroderma	0.000208	0.000417	CcSEcCtD
Ifosfamide—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000207	0.000415	CcSEcCtD
Ifosfamide—Diarrhoea—Azathioprine—systemic scleroderma	0.000206	0.000413	CcSEcCtD
Ifosfamide—Haemoglobin—Prednisone—systemic scleroderma	0.000205	0.000411	CcSEcCtD
Ifosfamide—Nausea—Captopril—systemic scleroderma	0.000205	0.000411	CcSEcCtD
Ifosfamide—Haemorrhage—Prednisone—systemic scleroderma	0.000204	0.000409	CcSEcCtD
Ifosfamide—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000204	0.000409	CcSEcCtD
Ifosfamide—Asthenia—Leflunomide—systemic scleroderma	0.000204	0.000409	CcSEcCtD
Ifosfamide—Hallucination—Prednisone—systemic scleroderma	0.000203	0.000407	CcSEcCtD
Ifosfamide—Pancytopenia—Methotrexate—systemic scleroderma	0.000203	0.000406	CcSEcCtD
Ifosfamide—Feeling abnormal—Lisinopril—systemic scleroderma	0.000201	0.000403	CcSEcCtD
Ifosfamide—Pruritus—Leflunomide—systemic scleroderma	0.000201	0.000403	CcSEcCtD
Ifosfamide—Connective tissue disorder—Prednisone—systemic scleroderma	0.000201	0.000402	CcSEcCtD
Ifosfamide—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.0002	0.000401	CcSEcCtD
Ifosfamide—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.0002	0.0004	CcSEcCtD
Ifosfamide—Dysuria—Methotrexate—systemic scleroderma	0.0002	0.000399	CcSEcCtD
Ifosfamide—Dizziness—Azathioprine—systemic scleroderma	0.000199	0.000399	CcSEcCtD
Ifosfamide—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000195	0.000391	CcSEcCtD
Ifosfamide—Asthenia—Mycophenolic acid—systemic scleroderma	0.000195	0.00039	CcSEcCtD
Ifosfamide—Diarrhoea—Leflunomide—systemic scleroderma	0.000195	0.00039	CcSEcCtD
Ifosfamide—Urticaria—Lisinopril—systemic scleroderma	0.000194	0.000389	CcSEcCtD
Ifosfamide—Abdominal pain—Lisinopril—systemic scleroderma	0.000193	0.000387	CcSEcCtD
Ifosfamide—Body temperature increased—Lisinopril—systemic scleroderma	0.000193	0.000387	CcSEcCtD
Ifosfamide—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000192	0.000385	CcSEcCtD
Ifosfamide—Pruritus—Mycophenolic acid—systemic scleroderma	0.000192	0.000384	CcSEcCtD
Ifosfamide—Vomiting—Azathioprine—systemic scleroderma	0.000192	0.000383	CcSEcCtD
Ifosfamide—Pneumonia—Methotrexate—systemic scleroderma	0.000191	0.000383	CcSEcCtD
Ifosfamide—Eye disorder—Prednisone—systemic scleroderma	0.000191	0.000382	CcSEcCtD
Ifosfamide—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000191	0.000382	CcSEcCtD
Ifosfamide—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.00019	0.000381	CcSEcCtD
Ifosfamide—Infestation NOS—Methotrexate—systemic scleroderma	0.00019	0.000381	CcSEcCtD
Ifosfamide—Infestation—Methotrexate—systemic scleroderma	0.00019	0.000381	CcSEcCtD
Ifosfamide—Rash—Azathioprine—systemic scleroderma	0.00019	0.00038	CcSEcCtD
Ifosfamide—Dermatitis—Azathioprine—systemic scleroderma	0.00019	0.00038	CcSEcCtD
Ifosfamide—Flushing—Prednisone—systemic scleroderma	0.00019	0.00038	CcSEcCtD
Ifosfamide—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000189	0.000378	CcSEcCtD
Ifosfamide—Dizziness—Leflunomide—systemic scleroderma	0.000188	0.000377	CcSEcCtD
Ifosfamide—Renal failure—Methotrexate—systemic scleroderma	0.000187	0.000374	CcSEcCtD
Ifosfamide—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000186	0.000373	CcSEcCtD
Ifosfamide—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000186	0.000372	CcSEcCtD
Ifosfamide—Stomatitis—Methotrexate—systemic scleroderma	0.000185	0.000371	CcSEcCtD
Ifosfamide—Angiopathy—Prednisone—systemic scleroderma	0.000185	0.000371	CcSEcCtD
Ifosfamide—Conjunctivitis—Methotrexate—systemic scleroderma	0.000185	0.00037	CcSEcCtD
Ifosfamide—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000185	0.00037	CcSEcCtD
Ifosfamide—Immune system disorder—Prednisone—systemic scleroderma	0.000185	0.00037	CcSEcCtD
Ifosfamide—Pain—Mycophenolate mofetil—systemic scleroderma	0.000183	0.000367	CcSEcCtD
Ifosfamide—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000183	0.000367	CcSEcCtD
Ifosfamide—Arrhythmia—Prednisone—systemic scleroderma	0.000183	0.000365	CcSEcCtD
Ifosfamide—Haematuria—Methotrexate—systemic scleroderma	0.000181	0.000363	CcSEcCtD
Ifosfamide—Vomiting—Leflunomide—systemic scleroderma	0.000181	0.000362	CcSEcCtD
Ifosfamide—Alopecia—Prednisone—systemic scleroderma	0.000181	0.000362	CcSEcCtD
Ifosfamide—Hypersensitivity—Lisinopril—systemic scleroderma	0.00018	0.000361	CcSEcCtD
Ifosfamide—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.00018	0.00036	CcSEcCtD
Ifosfamide—Dizziness—Mycophenolic acid—systemic scleroderma	0.000179	0.000359	CcSEcCtD
Ifosfamide—Rash—Leflunomide—systemic scleroderma	0.000179	0.000359	CcSEcCtD
Ifosfamide—Dermatitis—Leflunomide—systemic scleroderma	0.000179	0.000359	CcSEcCtD
Ifosfamide—Mental disorder—Prednisone—systemic scleroderma	0.000179	0.000358	CcSEcCtD
Ifosfamide—Nausea—Azathioprine—systemic scleroderma	0.000179	0.000358	CcSEcCtD
Ifosfamide—Malnutrition—Prednisone—systemic scleroderma	0.000178	0.000356	CcSEcCtD
Ifosfamide—Erythema—Prednisone—systemic scleroderma	0.000178	0.000356	CcSEcCtD
Ifosfamide—Agranulocytosis—Methotrexate—systemic scleroderma	0.000178	0.000355	CcSEcCtD
Ifosfamide—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000177	0.000353	CcSEcCtD
Ifosfamide—Asthenia—Lisinopril—systemic scleroderma	0.000175	0.000351	CcSEcCtD
Ifosfamide—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000175	0.000351	CcSEcCtD
Ifosfamide—Pruritus—Lisinopril—systemic scleroderma	0.000173	0.000346	CcSEcCtD
Ifosfamide—Vomiting—Mycophenolic acid—systemic scleroderma	0.000173	0.000345	CcSEcCtD
Ifosfamide—Haemoglobin—Methotrexate—systemic scleroderma	0.000172	0.000344	CcSEcCtD
Ifosfamide—Rash—Mycophenolic acid—systemic scleroderma	0.000171	0.000343	CcSEcCtD
Ifosfamide—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000171	0.000342	CcSEcCtD
Ifosfamide—Hepatitis—Methotrexate—systemic scleroderma	0.000171	0.000342	CcSEcCtD
Ifosfamide—Haemorrhage—Methotrexate—systemic scleroderma	0.000171	0.000342	CcSEcCtD
Ifosfamide—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.00017	0.000341	CcSEcCtD
Ifosfamide—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000169	0.000339	CcSEcCtD
Ifosfamide—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000169	0.000339	CcSEcCtD
Ifosfamide—Nausea—Leflunomide—systemic scleroderma	0.000169	0.000338	CcSEcCtD
Ifosfamide—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000169	0.000338	CcSEcCtD
Ifosfamide—Vision blurred—Prednisone—systemic scleroderma	0.000168	0.000336	CcSEcCtD
Ifosfamide—Urethral disorder—Methotrexate—systemic scleroderma	0.000167	0.000335	CcSEcCtD
Ifosfamide—Diarrhoea—Lisinopril—systemic scleroderma	0.000167	0.000335	CcSEcCtD
Ifosfamide—Ill-defined disorder—Prednisone—systemic scleroderma	0.000165	0.00033	CcSEcCtD
Ifosfamide—Visual impairment—Methotrexate—systemic scleroderma	0.000165	0.00033	CcSEcCtD
Ifosfamide—Anaemia—Prednisone—systemic scleroderma	0.000164	0.000329	CcSEcCtD
Ifosfamide—Agitation—Prednisone—systemic scleroderma	0.000163	0.000327	CcSEcCtD
Ifosfamide—Angioedema—Prednisone—systemic scleroderma	0.000163	0.000325	CcSEcCtD
Ifosfamide—Dizziness—Lisinopril—systemic scleroderma	0.000162	0.000324	CcSEcCtD
Ifosfamide—Erythema multiforme—Methotrexate—systemic scleroderma	0.000161	0.000323	CcSEcCtD
Ifosfamide—Nausea—Mycophenolic acid—systemic scleroderma	0.000161	0.000323	CcSEcCtD
Ifosfamide—Malaise—Prednisone—systemic scleroderma	0.00016	0.000321	CcSEcCtD
Ifosfamide—Vertigo—Prednisone—systemic scleroderma	0.00016	0.00032	CcSEcCtD
Ifosfamide—Eye disorder—Methotrexate—systemic scleroderma	0.00016	0.00032	CcSEcCtD
Ifosfamide—Tinnitus—Methotrexate—systemic scleroderma	0.000159	0.000319	CcSEcCtD
Ifosfamide—Cardiac disorder—Methotrexate—systemic scleroderma	0.000159	0.000317	CcSEcCtD
Ifosfamide—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000158	0.000316	CcSEcCtD
Ifosfamide—Vomiting—Lisinopril—systemic scleroderma	0.000155	0.000311	CcSEcCtD
Ifosfamide—Angiopathy—Methotrexate—systemic scleroderma	0.000155	0.00031	CcSEcCtD
Ifosfamide—Immune system disorder—Methotrexate—systemic scleroderma	0.000154	0.000309	CcSEcCtD
Ifosfamide—Rash—Lisinopril—systemic scleroderma	0.000154	0.000309	CcSEcCtD
Ifosfamide—Convulsion—Prednisone—systemic scleroderma	0.000154	0.000309	CcSEcCtD
Ifosfamide—Dermatitis—Lisinopril—systemic scleroderma	0.000154	0.000308	CcSEcCtD
Ifosfamide—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000154	0.000308	CcSEcCtD
Ifosfamide—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000154	0.000308	CcSEcCtD
Ifosfamide—Hypertension—Prednisone—systemic scleroderma	0.000154	0.000307	CcSEcCtD
Ifosfamide—Chills—Methotrexate—systemic scleroderma	0.000153	0.000307	CcSEcCtD
Ifosfamide—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000152	0.000303	CcSEcCtD
Ifosfamide—Myalgia—Prednisone—systemic scleroderma	0.000151	0.000303	CcSEcCtD
Ifosfamide—Arthralgia—Prednisone—systemic scleroderma	0.000151	0.000303	CcSEcCtD
Ifosfamide—Alopecia—Methotrexate—systemic scleroderma	0.000151	0.000302	CcSEcCtD
Ifosfamide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.00015	0.000301	CcSEcCtD
Ifosfamide—Discomfort—Prednisone—systemic scleroderma	0.00015	0.0003	CcSEcCtD
Ifosfamide—Mental disorder—Methotrexate—systemic scleroderma	0.00015	0.0003	CcSEcCtD
Ifosfamide—Erythema—Methotrexate—systemic scleroderma	0.000149	0.000298	CcSEcCtD
Ifosfamide—Malnutrition—Methotrexate—systemic scleroderma	0.000149	0.000298	CcSEcCtD
Ifosfamide—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000147	0.000293	CcSEcCtD
Ifosfamide—Nausea—Lisinopril—systemic scleroderma	0.000145	0.000291	CcSEcCtD
Ifosfamide—Anaphylactic shock—Prednisone—systemic scleroderma	0.000145	0.000291	CcSEcCtD
Ifosfamide—Oedema—Prednisone—systemic scleroderma	0.000145	0.000291	CcSEcCtD
Ifosfamide—Infection—Prednisone—systemic scleroderma	0.000144	0.000289	CcSEcCtD
Ifosfamide—Nervous system disorder—Prednisone—systemic scleroderma	0.000142	0.000285	CcSEcCtD
Ifosfamide—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000142	0.000284	CcSEcCtD
Ifosfamide—Skin disorder—Prednisone—systemic scleroderma	0.000141	0.000282	CcSEcCtD
Ifosfamide—Hyperhidrosis—Prednisone—systemic scleroderma	0.00014	0.000281	CcSEcCtD
Ifosfamide—Vision blurred—Methotrexate—systemic scleroderma	0.00014	0.000281	CcSEcCtD
Ifosfamide—Anorexia—Prednisone—systemic scleroderma	0.000138	0.000277	CcSEcCtD
Ifosfamide—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000138	0.000276	CcSEcCtD
Ifosfamide—Anaemia—Methotrexate—systemic scleroderma	0.000137	0.000275	CcSEcCtD
Ifosfamide—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000136	0.000273	CcSEcCtD
Ifosfamide—Rash—Mycophenolate mofetil—systemic scleroderma	0.000135	0.00027	CcSEcCtD
Ifosfamide—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000135	0.00027	CcSEcCtD
Ifosfamide—Malaise—Methotrexate—systemic scleroderma	0.000134	0.000268	CcSEcCtD
Ifosfamide—Vertigo—Methotrexate—systemic scleroderma	0.000134	0.000267	CcSEcCtD
Ifosfamide—Leukopenia—Methotrexate—systemic scleroderma	0.000133	0.000266	CcSEcCtD
Ifosfamide—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000132	0.000265	CcSEcCtD
Ifosfamide—Paraesthesia—Prednisone—systemic scleroderma	0.00013	0.000261	CcSEcCtD
Ifosfamide—Cough—Methotrexate—systemic scleroderma	0.00013	0.00026	CcSEcCtD
Ifosfamide—Convulsion—Methotrexate—systemic scleroderma	0.000129	0.000258	CcSEcCtD
Ifosfamide—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000127	0.000255	CcSEcCtD
Ifosfamide—Arthralgia—Methotrexate—systemic scleroderma	0.000127	0.000253	CcSEcCtD
Ifosfamide—Myalgia—Methotrexate—systemic scleroderma	0.000127	0.000253	CcSEcCtD
Ifosfamide—Chest pain—Methotrexate—systemic scleroderma	0.000127	0.000253	CcSEcCtD
Ifosfamide—Decreased appetite—Prednisone—systemic scleroderma	0.000126	0.000253	CcSEcCtD
Ifosfamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000126	0.000252	CcSEcCtD
Ifosfamide—Fatigue—Prednisone—systemic scleroderma	0.000125	0.000251	CcSEcCtD
Ifosfamide—Discomfort—Methotrexate—systemic scleroderma	0.000125	0.00025	CcSEcCtD
Ifosfamide—Constipation—Prednisone—systemic scleroderma	0.000124	0.000249	CcSEcCtD
Ifosfamide—Confusional state—Methotrexate—systemic scleroderma	0.000122	0.000245	CcSEcCtD
Ifosfamide—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000121	0.000243	CcSEcCtD
Ifosfamide—Infection—Methotrexate—systemic scleroderma	0.000121	0.000241	CcSEcCtD
Ifosfamide—Feeling abnormal—Prednisone—systemic scleroderma	0.00012	0.00024	CcSEcCtD
Ifosfamide—Nervous system disorder—Methotrexate—systemic scleroderma	0.000119	0.000238	CcSEcCtD
Ifosfamide—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000119	0.000238	CcSEcCtD
Ifosfamide—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000119	0.000238	CcSEcCtD
Ifosfamide—Skin disorder—Methotrexate—systemic scleroderma	0.000118	0.000236	CcSEcCtD
Ifosfamide—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000117	0.000235	CcSEcCtD
Ifosfamide—Anorexia—Methotrexate—systemic scleroderma	0.000116	0.000232	CcSEcCtD
Ifosfamide—Urticaria—Prednisone—systemic scleroderma	0.000115	0.000231	CcSEcCtD
Ifosfamide—Abdominal pain—Prednisone—systemic scleroderma	0.000115	0.00023	CcSEcCtD
Ifosfamide—Body temperature increased—Prednisone—systemic scleroderma	0.000115	0.00023	CcSEcCtD
Ifosfamide—Hypotension—Methotrexate—systemic scleroderma	0.000113	0.000227	CcSEcCtD
Ifosfamide—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000111	0.000221	CcSEcCtD
Ifosfamide—Paraesthesia—Methotrexate—systemic scleroderma	0.000109	0.000218	CcSEcCtD
Ifosfamide—Dyspnoea—Methotrexate—systemic scleroderma	0.000108	0.000217	CcSEcCtD
Ifosfamide—Somnolence—Methotrexate—systemic scleroderma	0.000108	0.000216	CcSEcCtD
Ifosfamide—Hypersensitivity—Prednisone—systemic scleroderma	0.000107	0.000214	CcSEcCtD
Ifosfamide—Decreased appetite—Methotrexate—systemic scleroderma	0.000105	0.000211	CcSEcCtD
Ifosfamide—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000105	0.00021	CcSEcCtD
Ifosfamide—Fatigue—Methotrexate—systemic scleroderma	0.000105	0.000209	CcSEcCtD
Ifosfamide—Asthenia—Prednisone—systemic scleroderma	0.000104	0.000209	CcSEcCtD
Ifosfamide—Pain—Methotrexate—systemic scleroderma	0.000104	0.000208	CcSEcCtD
Ifosfamide—Pruritus—Prednisone—systemic scleroderma	0.000103	0.000206	CcSEcCtD
Ifosfamide—Feeling abnormal—Methotrexate—systemic scleroderma	0.0001	0.0002	CcSEcCtD
Ifosfamide—Diarrhoea—Prednisone—systemic scleroderma	9.93e-05	0.000199	CcSEcCtD
Ifosfamide—Gastrointestinal pain—Methotrexate—systemic scleroderma	9.92e-05	0.000199	CcSEcCtD
Ifosfamide—Urticaria—Methotrexate—systemic scleroderma	9.64e-05	0.000193	CcSEcCtD
Ifosfamide—Dizziness—Prednisone—systemic scleroderma	9.6e-05	0.000192	CcSEcCtD
Ifosfamide—Body temperature increased—Methotrexate—systemic scleroderma	9.59e-05	0.000192	CcSEcCtD
Ifosfamide—Abdominal pain—Methotrexate—systemic scleroderma	9.59e-05	0.000192	CcSEcCtD
Ifosfamide—Vomiting—Prednisone—systemic scleroderma	9.23e-05	0.000185	CcSEcCtD
Ifosfamide—Rash—Prednisone—systemic scleroderma	9.15e-05	0.000183	CcSEcCtD
Ifosfamide—Dermatitis—Prednisone—systemic scleroderma	9.15e-05	0.000183	CcSEcCtD
Ifosfamide—Hypersensitivity—Methotrexate—systemic scleroderma	8.94e-05	0.000179	CcSEcCtD
Ifosfamide—Asthenia—Methotrexate—systemic scleroderma	8.71e-05	0.000174	CcSEcCtD
Ifosfamide—Nausea—Prednisone—systemic scleroderma	8.62e-05	0.000173	CcSEcCtD
Ifosfamide—Pruritus—Methotrexate—systemic scleroderma	8.58e-05	0.000172	CcSEcCtD
Ifosfamide—Diarrhoea—Methotrexate—systemic scleroderma	8.3e-05	0.000166	CcSEcCtD
Ifosfamide—Dizziness—Methotrexate—systemic scleroderma	8.02e-05	0.000161	CcSEcCtD
Ifosfamide—Vomiting—Methotrexate—systemic scleroderma	7.71e-05	0.000154	CcSEcCtD
Ifosfamide—Rash—Methotrexate—systemic scleroderma	7.65e-05	0.000153	CcSEcCtD
Ifosfamide—Dermatitis—Methotrexate—systemic scleroderma	7.64e-05	0.000153	CcSEcCtD
Ifosfamide—Nausea—Methotrexate—systemic scleroderma	7.21e-05	0.000144	CcSEcCtD
